

Kunihiko Kobayashi

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/9249743/kunihiko-kobayashi-publications-by-year.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

29
papers

759
citations

12
h-index

27
g-index

34
ext. papers

1,121
ext. citations

3.8
avg, IF

4.02
L-index

#	Paper	IF	Citations
29	Efficacy and Feasibility of Programmed Death-1/Programmed Death Ligand-1 Blockade Therapy in Non-Small Cell Lung Cancer Patients With High Antinuclear Antibody Titers. <i>Frontiers in Oncology</i> , 2021 , 11, 610952	5.3	1
28	A phase II study of first-line afatinib for patients aged ≥ 5 years with EGFR mutation-positive advanced non-small cell lung cancer: North East Japan Study Group trial NEJ027. <i>BMC Cancer</i> , 2021 , 21, 208	4.8	3
27	Post-Progression Survival Influences Overall Survival among Patients with Advanced Non-Small Cell Lung Cancer Undergoing First-Line Pembrolizumab Monotherapy. <i>Oncology</i> , 2021 , 99, 562-570	3.6	2
26	Effectiveness of EGFR-TKI rechallenge immediately after PD-1 blockade failure. <i>Thoracic Cancer</i> , 2021 , 12, 864-873	3.2	4
25	Clinical impact of post-progression survival on overall survival in patients receiving nivolumab monotherapy as a second-line treatment for advanced non-small cell lung cancer. <i>Thoracic Cancer</i> , 2021 , 12, 1171-1179	3.2	1
24	Pretreatment Glasgow prognostic score predicts survival among patients with high PD-L1 expression administered first-line pembrolizumab monotherapy for non-small cell lung cancer. <i>Cancer Medicine</i> , 2021 , 10, 6971-6984	4.8	3
23	Combination of immune check inhibitor and immunomodulatory arabinomannan extracted from : A case report. <i>Molecular and Clinical Oncology</i> , 2021 , 15, 227	1.6	0
22	Bevacizumab plus chemotherapy in nonsquamous non-small cell lung cancer patients with malignant pleural effusion uncontrolled by tube drainage or pleurodesis: A phase II study North East Japan Study group trial NEJ013B. <i>Thoracic Cancer</i> , 2020 , 11, 1876-1884	3.2	2
21	Chemoradiotherapy followed by durvalumab in patients with unresectable advanced non-small cell lung cancer: Management of adverse events. <i>Thoracic Cancer</i> , 2020 , 11, 1280-1287	3.2	13
20	Potential of FDG-PET as Prognostic Significance after anti-PD-1 Antibody against Patients with Previously Treated Non-Small Cell Lung Cancer. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	20
19	Gefitinib Alone Versus Gefitinib Plus Chemotherapy for Non-Small-Cell Lung Cancer With Mutated Epidermal Growth Factor Receptor: NEJ009 Study. <i>Journal of Clinical Oncology</i> , 2020 , 38, 115-123	2.2	155
18	A phase II study of daily carboplatin plus irradiation followed by durvalumab for stage III non-small cell lung cancer patients with PS 2 up to 74 years old and patients with PS 0 or 1 from 75 years: NEJ039A (trial in progress). <i>BMC Cancer</i> , 2020 , 20, 961	4.8	1
17	Primary thymic adenocarcinoma with an aggressive clinical course: An autopsy case showing signet ring cell-like features. <i>Thoracic Cancer</i> , 2020 , 11, 3609-3613	3.2	1
16	Tumor metabolic volume by F-FDG-PET as a prognostic predictor of first-line pembrolizumab for NSCLC patients with PD-L1 ≥ 50 . <i>Scientific Reports</i> , 2020 , 10, 14990	4.9	6
15	Recovery of the Sensitivity to Anti-PD-1 Antibody by Celecoxib in Lung Cancer. <i>Anticancer Research</i> , 2020 , 40, 5309-5311	2.3	2
14	Clinical difference between discontinuation and retreatment with nivolumab after immune-related adverse events in patients with lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2019 , 84, 873-880	3.5	18
13	Radiotherapy is an independent prognostic marker of favorable prognosis in non-small cell lung cancer patients after treatment with the immune checkpoint inhibitor, nivolumab. <i>Thoracic Cancer</i> , 2019 , 10, 992-1000	3.2	30

12	Different incidence of interstitial lung disease according to different kinds of EGFR-tyrosine kinase inhibitors administered immediately before and/or after anti-PD-1 antibodies in lung cancer. <i>Thoracic Cancer</i> , 2019 , 10, 975-979	3.2	16
11	Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial. <i>Lancet Oncology</i> , 2019 , 20, 625-635	21.7	264
10	Improved efficacy of ramucirumab plus docetaxel after nivolumab failure in previously treated non-small cell lung cancer patients. <i>Thoracic Cancer</i> , 2019 , 10, 775-781	3.2	38
9	Re-challenge of afatinib after 1st generation EGFR-TKI failure in patients with previously treated non-small cell lung cancer harboring EGFR mutation. <i>Cancer Chemotherapy and Pharmacology</i> , 2019 , 83, 817-825	3.5	4
8	A phase II study of bevacizumab with carboplatin-pemetrexed in non-squamous non-small cell lung carcinoma patients with malignant pleural effusions: North East Japan Study Group Trial NEJ013A. <i>Lung Cancer</i> , 2016 , 99, 131-6	5.9	26
7	CT Features of Epidermal Growth Factor Receptor-Mutated Adenocarcinoma of the Lung: Comparison with Nonmutated Adenocarcinoma. <i>Journal of Thoracic Oncology</i> , 2016 , 11, 819-26	8.9	45
6	A phase II study of erlotinib monotherapy in pre-treated non-small cell lung cancer without EGFR gene mutation who have never/light smoking history: re-evaluation of EGFR gene status (NEJ006/TCOG0903). <i>Lung Cancer</i> , 2014 , 86, 195-200	5.9	6
5	Epidermal growth factor receptor (EGFR) mutation and personalized therapy in advanced nonsmall cell lung cancer (NSCLC). <i>Targeted Oncology</i> , 2013 , 8, 27-33	5	82
4	Randomized phase III trial of S-1 plus cisplatin versus docetaxel plus cisplatin for advanced non-small-cell lung cancer (TCOG0701).. <i>Journal of Clinical Oncology</i> , 2012 , 30, 7515-7515	2.2	13
3	Content Validity and Feasibility of the Care Notebook to Assess Cancer-Related Quality of Life in Hawaii. <i>Annals of Cancer Research and Therapy</i> , 2012 , 20, 68-72	0.2	
2	A phase II study of erlotinib monotherpay in patients with previously treated advanced non-small cell lung cancer (NSCLC) without EGFR gene mutation who have never/light smoking history: NEJ006/TCOG0903.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 7561-7561	2.2	1
1	First-line gefitinib for elderly patients with advanced non-small cell lung cancer (NSCLC) harboring EGFR mutations: A combined analysis of NEJ studies.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 7563-7563	2.2	0